This post is from a suggested group
Therapeutic Paradigms for Differentiated Thyroid Cancer (DTC)
Differentiated Thyroid Cancer (DTC), which includes papillary and follicular subtypes, is generally characterized by a high survival rate, but advanced cases require complex multimodal therapy.
Standard and Targeted Care
Radioactive Iodine (RAI) Therapy: Because thyroid cells have a unique affinity for iodine, RAI is used to ablate remnant thyroid tissue or metastatic cells after surgery.
Tyrosine Kinase Inhibitors (TKIs): For patients with "RAI-refractory" disease, TKIs like Lenvatinib or Sorafenib are used. These drugs block the signaling of vascular endothelial growth factor (VEGF), effectively cutting off the blood supply to the tumor and inhibiting its ability to grow.
_edited.jpg)